Tiziana Pressiani
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 121 publications
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study.
Journal: ESMO gastrointestinal oncology
Published: May 22, 2026
Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.
Journal: Journal of hepatology
Published: April 09, 2026
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab.
Journal: International journal of cancer
Published: March 23, 2026
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting.
Journal: International journal of cancer
Published: February 15, 2026
Predicting Decompensation in Unresectable Hepatocellular Carcinoma on Atezolizumab Plus Bevacizumab: The ARTE Score.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: February 13, 2026
Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data From the LOR-HCC (Lombardy Real-World HCC Group).
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: January 24, 2026
Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study.
Journal: Hepatology (Baltimore, Md.)
Published: November 22, 2025
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions.
Journal: Expert opinion on biological therapy
Published: September 05, 2025
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: August 15, 2025
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 01, 2025
Last Updated: 09/26/2026